TBXT does not engage directly in typical pharmacokinetic or pharmacodynamic interactions that affect drug efficacy or safety based on genetic variation, as its role is more aligned with developmental processes rather than drug metabolism. The speculative interaction of TBXT with flunisolide, an inflammatory and immune response modifier, hints at potential but unconfirmed pharmacogenetic interplay through developmental pathway modulation rather than conventional drug action mechanisms.